Nuclear factor kappa B as a potential target for pharmacological correction endothelium-associated pathology / V.A. Ragulina, D.A. Kostina, A.P. Dovgan, Y.E. Burda, S.V. Nadezhdin // Research results: pharmacology and clinical pharmacology. – 2017. – Vol. 3, №1 – P. 114-124.

NUCLEAR FACTOR KAPPA B AS A POTENTIAL TARGET FOR PHARMACOLOGICAL CORRECTION ENDOTHELIUM-ASSOCIATED PATHOLOGY

UDK: 615.225:611.018.74
DOI: 10.18413/2500-235X-2017-3-1-114-124

Ragulina V.A.1,
Kostina D.A.2,
Dovgan A.P.2,
Burda Y.E.2,
Nadezhdin S.V.2

1 Kursk State Medical University, 3, Karl Marx St., Kursk, 305041,
2 Belgorod State University, 85 Pobedy St., Belgorod, 308015, Russia. e-mail: kostina_da@bsu.edu.ru

Abstract. The nuclear factor kappa B (NF-κB) is one of transcription factors. A high interest in studying the biological role of the signal system and its contribution to the development of cardiovascular, oncological and autoimmune diseases is obvious. A number of stimuli (pro-inflammatory cytokines: tumor necrosis factor α, interleukin 1β, ligand CD40 and others) trigger the canonical and non-canonical pathways of NF-κB signaling, which increase the expression of genes regulating synthesis of cytokines and chemokines, cell proliferation and differentiation, angiogenesis, immune reactions and apoptosis. However, pathological activation of NF-κB violates the balance of substances participating in the normal activity of the cardiovascular system. This leads to the development and progression of endothelium-associated pathology and comorbidity. Contribution of pathological activation the NF-κB signaling system in the formation of vicious circles in atherosclerosis, coronary heart disease, pulmonary hypertension, ischemic-reperfusion injury, is not subject to doubt. Thus, the search for new therapeutic targets and strategies for modulating the activity of the NF-κB signaling pathway is one of the key strategies for the development of experimental pharmacology. Another important aspect of studying the pharmacological activity of NF-κB activity modulators is the choice of a valid and easily reproducible way of assessing the activity of this system.

Keywords: nuclear factor kappa B, NF-κB, endothelial dysfunction, ischemia-reperfusion, pharmacological correction, comorbidity.

Introduction
There are more information about the intracellular processes that occur during the activation of this pathway, biological role, contribution to the pathogenesis of the disease and methods of modulating the activity of nuclear factor are appearing every year. Increasing interest in the problem can be seen by analyzing the number of publications on request «NF kappa B», carried out in the PubMed system (fig. 1).

The role of signaling system nuclear factor kappa B in the development of various diseases, including the endothelium-associated [1, 2, 3, 4, 5, 6, 7] is presented in table 1.
RESEARCH RESULT

PHARMACOLOGY AND CLINICAL PHARMACOLOGY

Nuclear factor kappa B as a potential target for pharmacological correction endothelium-associated pathology / V.A. Ragulina, D.A. Kostina, A.P. Dovgan, V.E. Burda, S.V. Nadezhdin // Research result: pharmacology and clinical pharmacology. – 2017. – Vol. 3, №1 – P. 114-124.

Figure 1. Dynamics of the number of publications on the request «NF kappa B» in the PubMed system

| Disease                                      | Dependence on the NF-κB activity                           | Reference                                                                 |
|----------------------------------------------|------------------------------------------------------------|---------------------------------------------------------------------------|
| Atherosclerosis                              | Increased activity of NF-κB                                | B. Pamukcu et al., 2011 [8]; C. Monaco et al., 2004 [9]; W. Zhang et al., 2009 [1]; |
| Acute myocardial infarction and ischemia-reperfusion | Increased activity of NF-κB                              | G. Valen et al., 2001 [11]; A. Kis et al., 2003 [12]; B. Zingarelli et al., 2002 [13]; |
| Pulmonary hypertension                       | Increased activity of NF-κB                                | S. Hosokawa et al., 2013 [14];                                            |
| Chronic renal failure                        | Increased activity of NF-κB                                | G. Rangan et al., 2009 [15];                                             |
| Chronic obstructive pulmonary disease (COPD) and asthma | Increased activity of NF-κB                              | M.R. Edwards et al., 2009 [16]; M. Schuliga, 2015 [17];                 |
| Rheumatoid arthritis                         | Increased activity of NF-κB                                | M. Feldmann et al., 2002 [18]; R.E. Simmonds, et al., 2008 [19];         |
| Diabetes mellitus and its complications       | Increased activity of NF-κB                                | I.P. Kaydashev, 2011 [20]; S. Patel et al., 2009 [21];                   |

The role of the signaling system of the nuclear factor kappa B in the development of diseases

Table 1

Signaling system nuclear factor kappa B

Nuclear factor kappa B (NF-κB) is a transcription factor, discovered by Sen and Baltimore in 1980s [22], is widely expressed in many mammalian cells. NF-κB plays an important role in the innate immune system and stimulates the synthesis of proinflammatory mediators such as cytokines, in response to the activation of Toll-like receptors (TLR) by bacterial lipopolysaccharides.

NF-κB complex consists of a family of dimeric transcription factors including RelA (p65), RelB, c-Rel, NFκB1 (p50) and NFκB2 (p52) [23]. They all contain REL-homology domain (RHD), which is responsible for NF-κB intranuclear transport and DNA binding. In addition, p65, c-Rel and Rel-B contain transactivation domain (TAD), which is required for gene activation. P50 and p52 subunits are produced from precursors – p105 and p100, and subjected to dimerization with TAD-containing domain to activate transcription of genes. Thus, homodimers of p50 and p52 act as repressors of gene expression, whereas p65, c-Rel and Rel-B in any combination, including p50 and p52, transcription activators play a role.
In unstimulated cells, NF-κB dimers are united in the cytoplasm by RHDs with inhibitory proteins of NF-κB, called IκBs. Stimulus-mediated activation of IκB-kinase (IKK) relates to IκBs degradation to the release and activation of NF-κB [24]. IκB family includes IκBα, IκBβ, IκBγ, IκBδ / p100, IκBε and B-cell lymphoma 3-encoded protein (Bcl-3). All of them have several ankyrin repeats (composed of 30-33 amino acids), binding with Rel-domain of NF-κB, maintaining nuclear factor in the cytoplasm [25, 26]. In activating of signaling pathway IκB exposed to phosphorylation and ubiquitination. It changes conformational structure of molecules, determining their recognition and destruction in the proteasome. IκBα is best understood. It is strongly associated with the p65 subunit of NF-κB, inhibiting its activity. Stimulation of cells leads to the phosphorylation of IκBα (32 and 36 serine residues) and bonding (at 21 and 22 lysine residues), ubiquitin which is ATP-dependent proteolysis in a 26S-proteasome system complex [27, 28]. This leads to the release of NF-κB, which after further phosphorylation is able to migrate to the cell nucleus and is the site of action. The transcriptional activity of NF-κB appears within minutes after stimulation [25].

Canonical activation signaling pathway of nuclear factor kappa B induced by exposure to tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), or ligands Toll-like receptors (TLR) (bacterial lipopolysaccharide and others) (fig. 2).

A common point of application for these incentives is IκB-kinase composed of two catalytic subunits, IKKα and IKKβ, and a regulatory subunit – NEMO, also known as IKKγ. IKK phosphorylates IκBα at serine residues 32 and 36, resulting ubiquitination in 21 and 22 lysines and subsequent degradation by the 26S proteasome [29]. It means, that IκBα is rapidly degraded under the activation of canonical pathway NF-KB, which results as the release of a plurality of nuclear factor dimers system. The main target IκBα probably is the p65/p50 heterodimer. The crystal structure of IκBα bound heterodimer with p65/p50 shows that protein IκBα masks the nuclear localization sequence (NLS) only in the p65, whereas p50 NLS in remains of exposed [30]. NLS was exposed in p50 in combination with the nuclear export sequence (NES) in IκBα and p65 regulate the circulation of IκBα / NF-κB complexes between the nucleus and cytoplasm, despite the almost exclusive cytosolic localization of the complex [30, 31]. Degradation of IκBα changes the dynamic balance between cytosolic and nuclear localization of NF-κB in favor of nuclear, allowing p50 / p65 to accumulate in the nucleus and activate

Figure 2. The canonical and non-canonical pathway activation signaling pathway nuclear factor kappa B [29]
gene transcription. IκBα, which can enter the nucleus, NF-κB displaces from its association with the DNA, and transports it back to the cytoplasm releasing negative feedback [32].

Non-canonical pathway activation of the signaling pathway of the nuclear factor kappa B is mediated through receptors of the TNF family (TNFR) including B-cell activating factor (BAFF), CD40 ligand, etc., induces NF-κB activation through a different path. NEMO-independent protein kinase NIK. It phosphorylates and activates IKKα [24, 26]. IKKα phosphorylates p100 on two serine residues at the C-end containing ankyrin repeats making RHD domain (p52) intact. Then p52 dimerizes with its partner Rel-B, to induce a program of gene expression, which is necessary for the maturation and activation of B cells [23]. Moreover, in one study at knockout IKKα−/− mice, the ability of potential signaling pathway activated NF-κB to influence the normal epidermal differentiation and morphology of skeleton has been demonstrated [33].

**The biological role of NF-κB**

Signaling pathway NF-κB is involved in the transcriptional control of genes coding for the set of biological processes (fig. 3).

Most of the genes that are under the transcriptional control of NF-κB, encode the synthesis of biologically active substances involved in the immune response and inflammatory reactions [34, 35]. These biologically active substances include cytokines (TNF-α, IL-1β, IL-2, 3, 6, 12, granulocyte macrophage colony-stimulating factor (GM-CSF), acute phase proteins (C-reactive protein ), chemokines (monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1 (MIP-1), several β-chemokines), and adhesion molecules (inter-cellular adhesion molecule type 1 (ICAM-1), E-selectin and the vascular cell adhesion molecule (VCAM-1)) [36, 37, 38, 39, 40, 41].

Furthermore, NF-κB increases receptor (CD80 / 81, TLR-2) expression and proteins presenting antigen (MHC class I and β2-microglobulin) on immune cells, which allows to properly implement the innate and adaptive immune responses [37, 41].

Other biological role of NF-κB is the regulation of apoptosis. Interestingly, NF-κB regulates the transcription of pro-apoptotic, (Bim, Bax, Fas and caspase 11) and anti-apoptotic (X-linked inhibitor of apoptosis protein (XIAP), Bcl-2, cFlip) gene [41, 42, 43]. Thus, with one hand activation of the signaling pathway protects cells from death in response to damage factors (radiation, viruses, bacteria etc.), and the other hand is prevent carcinogenesis limits the spread of infection.

Other genes category regulated NF-κB system includes growth factors such as nerve growth factor (NGF), vascular endothelial growth factor (VEGF),
insulin-like growth factor-binding protein (IGFBP), bone morphogenetic protein (BMP) and the fibroblast growth factor (FGF) [44, 45, 46].

The role of NF-κB in the development of cardiovascular diseases

Endothelial dysfunction. Endothelial dysfunction is a marker and one of the early stages in the development of cardiovascular disease [47, 48, 49, 50, 51].

Some potential target genes under the transcriptional control of NF-κB, contribute to the development of "proatherogenic" phenotype endothelial dysfunction. These genes encode the synthesis of pro-inflammatory molecules such as IL-6, TNF-α, MCP-1, a receptor for advanced glycation end-products (RAGE) [52, 53]. On the other hand, the activation of NF-κB signaling pathway can lead to the development of oxidative stress with the formation of reactive oxygen species by enhancing NADPH oxidase activity [54].

Thus, in one pre-clinical trial in mice they confirmed hypothesis that increased expression of NF-κB results in a decrease in endothelium-independent vasorelaxation and development of endothelial dysfunction [55].

Involvement signaling pathway of NF-κB to the development of endothelial dysfunction also confirmed in clinical studies. So, in the elderly (n = 14) were identified violations of the processes of endothelium-dependent vasodilation, which, according to the authors was associated with increased nuclear translocation of NF-κB in the cells of the vascular endothelium. This increase in nuclear localization was associated with a decrease in the expression of IκBα [56].

Atherosclerosis. One of the first stages of development of atherosclerosis is considered modification of low density lipoprotein (LDL) in the vessel wall, resulting in local inflammation, release of chemokines and increasing adhesion molecule expression on the endothelial cell surface [52]. NF-κB can be one of the inducers of these changes.

Firstly, under the transcriptional control of NF-κB is one of the important chemokines – MCP-1, which promotes primary migration of monocytes, are key cells in the early stage atherosclerotic plaque formation [8, 52]. Secondly, increased expression of adhesion molecules, including P-selectin, E-selectin, ICAM-1 and VCAM-1, which involved in process of atherogenesis [57]. Third, recently, much attention is paid to the activity of matrix metalloproteinases (MMPs) in atherosclerosis pathogenesis, that contribute to invasion of inflammatory cells into the vessel wall, smooth muscle cell migration, and remodeling of an intercellular matrix involved in maintaining the oxidative stress [58].

NF-κB activation in endothelial cells during early atherogenesis stages is able to achieve by complex circuits of induction by many different stimuli. These agents include oxidized LDL, advanced glycation end-products [52], proinflammatory cytokines produced at the site of injury [8] or bacterial lipopolysaccharides [59].

One of the biological roles of signaling NF-κB is involved in the process of inflammation, which in the development of atherosclerosis has become an important pathogenetic link lies in increasing the synthesis of proinflammatory cytokines (TNF-α, IL-1, IL-6 et al.), and decreased production of inflammatory (IL-10). Violation of balance of biologically active substances, demonstrated in preclinical studies [60, 61, 62, 63], contributes to more rapid development and progression of atherosclerosis and endothelial dysfunction.

These data show that the early stages of atherosclerosis, such as lipoprotein modification, activation of chemotaxis, adhesion and oxidative stress, maintaining chronic inflammation may vary depending on the activity of NF-κB signaling pathway.

Ischemia-reperfusion. With the increasing prevalence of cardiovascular disease and diabetes, as well as the rapid development of cardiac surgery, more acutely the question arises about the pathogenesis and approaches to pharmacological correction of ischemia-reperfusion injury of the heart [64, 65], liver [66, 67], brain [68, 69], retina [70, 71], placenta [72, 73].

It is known that ischemia and ischemia / reperfusion results in activation of NF-κB in the cells of the coronary arteries. This in turn leads to increased synthesis of pro-inflammatory cytokines, adhesion molecules (ICAM-1, P-selectin), which promotes the migration of inflammatory cells into the damaged center [74]. This process has been documented in clinical trials [75]. Since inflammation causes tissue damage, NF-κB activity modulation during ischemia / reperfusion injury is one of the potential targets for reducing the volume and reduce the damage risk of complications.

Methods for modulating the activity of a signaling pathway NF-κB. Increased activity of the signaling pathway NF-κB in the pathogenesis of many diseases, forced scientists to search for drugs, the mechanism of action of which is directed to modulation of the activity of this factor.
One of the first drugs for which was demonstrated by the ability to inhibit NF-κB, were cytotoxic agents and steroids. Perhaps this is due to the significant contribution of this signaling pathway in the pathogenesis of malignancies. A potential pharmacodynamic effect of glucocorticoids and cytotoxic drugs is the induction of synthesis IkBα [76].

The ability to inhibit NF-κB for drugs that are widely used in clinical practice for the treatment of cardiovascular and metabolic diseases can be attributed pleiotropic properties.

One of the most studied drug-inhibitors NF-κB from the group of antiplatelet agents is acetylsalicylic acid (ASA). The mechanism of inhibition of ASA and sodium salicylate caused by binding and blocking ATP-site IKKβ [77], thereby reducing the synthesis of proinflammatory cytokines and adhesion molecules [78] and the damaging effect of angiotensin II on potential target organs [79]. Thus, in one pre-clinical studies was demonstrated that low-dose aspirin suppress chronic inflammation and increased stability of atherosclerotic plaque, that is, exhibit antiatherogenic effects [80].

Another pharmaceutical group with numerous pleiotropic effects are inhibitors of HMG-CoA reductase inhibitors (statins). One potential explanation for the presence of their pleiotropic effects is their inhibitory effect on NF-κB, associated with the induction and stabilization of the endogenous inhibitor – IkBα [81]. At present time, much attention is paid to the effects of statin-related effects on receptors, peroxisome proliferators-activated (PPAR). PPARs play an important role in energy homeostasis and in the regulation of inflammatory responses [8]. It has been shown that statins (such as agonists, PPARγ) inhibite LPS-induced production of TNF-α, VCAM-1, MCP-1 by inhibiting the transcriptional activity of NF-κB [82]. Perhaps, PPARs agonists, exercise their effects by binding to RelA domain signaling pathway [83]. Another group of lipid-lowering drugs, realizing their pleiotropic effects through PPARs, are fribates [84]. Thus, some groups of hypolipidemic agents realize their effects through direct inhibition of NF-κB, or by acting on PPARs, which reduces production of proinflammatory cytokines (TNF-α, IL-1, IL-6), chemokines and growth factors and slow the progression of endothelial dysfunction and cardiovascular diseases.

In addition, certain polyunsaturated fatty acids (PUFAs) may exhibit anti-inflammatory effects by selectively inhibiting IkB kinase, which allows their use as anti-inflammatory agents in the treatment of atherosclerosis therapy [8].

Antioxidants have been suggested as possible inhibitors of NF-κB many years ago [85]. One possible mechanism of action is the inhibition of the growth activity of NF-κB in response to various stimuli (IL-1, LPS, TNF-α) [86]. On the other hand, the antioxidants can inhibit IKK, minimizing the degradation of IkBα [85]. For compounds of phenolic nature inhibitory activity described in the signaling pathway is realized through the reduction of NF-κB binding to DNA through RHD [87]. Promising pharmacological agents of the antioxidant properties of the group with inhibitors NF-κB, in our opinion, are the derivatives of cinnamic acid [88, 89].

However, the decrease in activity of NF-κB, can be dangerous because of the involvement of the signaling system in the regulation of immunity and its antiapoptotic role.

For determining the activity of NF-κB currently there are different approaches, among which you can choose the best for your study, and sometimes the activity understand the common expression of NF-κB, by the ability to inhibit NF-κB, in our opinion, is the Western blot [90]. Moreover, despite the absence of direct criteria of activity definition immunohistochemical or Western blot sections, software for morphometric or densitometric analysis, for example, the program ImageJ, allows quantitative assessment of prote expression and statistical processing of the obtained results [93]. Finally, test systems exist for enzyme-linked immunosorbent assay determination of p65 NF-κB, which are also used in scientific research [94, 95].

Thus, modulation of the activity of the signaling pathway nuclear factor kappa B and methods of the activity evaluation, requires further study for the creation of new, effective and safe group of drugs for the prevention and treatment of endothelium-associated pathology.

Conclusion

Signaling system NF-κB is a significant contributor to the development of endothelium -
associated disease by altering the expression of genes responsible for the persistence of inflammation, proliferation, cell migration and apoptosis. This can be attributed to the system of nuclear factor κB to a potential target for the creation of innovation-targeted therapies to reduce mortality from socially significant diseases.

References

1. Оценка динамики функциональных и биохимических показателей при моделировании гипергомоцистенин и L-NМЕ-индуцированного дефицита NO / M.B. Корокин, М.В. Покровский, В. И. Кочкарёв, О.С. Гудырев, Л.В. Корокина, Т.Г. Покровская, В.А. Савин // Научные ведомости БелГУ. Серия: Медицина. Фармация. – 2013. – №18 (161) – С. 255-260. [eLIBRARY] [Full text]

2. Study of the microcirculation level in bone with osteoporosis and osteoporotic fractures during therapy with recombinant erythropoietin, rosuvastatin and their combinations / D.S.R Rajkumar, O.S. Gudreyev, A.V. Faitelson, M.V. Pokrovskii // Research result: pharmacology and clinical pharmacology. – 2015. – Vol.1, №1 (1). – P. 47-50, doi: 10.18413/2500-235X-2015-1-4-57-60 [Full text]

3. Koklin, I.S. Use of selective inhibitors of arginase 2 and tadalafil in combined compensation of homocysteine-induced endothelial dysfunction / I.S. Koklin // Research result: pharmacology and clinical pharmacology. – 2015. – Vol. 1, №1 (1). – P. 13-19,doi: 10.18413/2500-235X-2015-1-4-15-20[Full text]

4. Approaches to pharmacological correction of endothelial dysfunction associated with metabolic endotoxemia / D.A. Kostina, T.G. Pokrovskaya, M.V. Pokrovskii, G.A. Lazareva, V.Y. Provotorov, A.A. Stepchenko // International Journal of Pharmacy and Technology. – 2016. – Vol. 8 (2). – P. 14291-14299. [eLIBRARY] [Full text]

5. Pharmacological correction of L-NМЕ-induced oxygen deficiency with derivatives of 3-(2,2,2-trimethylhydrazinium) propionate / S.Y. Skachilova, O.G. Kesarev, L.M. Danilenko, N.A. Bystrova, A.A. Dolzhikov, S.B. Nikolaev // Research result: pharmacology and clinical pharmacology. – 2016. – V.2, №1 (2). – P. 36-41 [eLIBRARY] [Full text]

6. Endothelioprotective property of the combination of the thiotic acid and rosuvastatin shown in the endothelial dysfunction models / O.V. Molchanova, T.G. Pokrovskaya, S.V. Povetkin, K.M. Reznikov // Research result: pharmacology and clinical pharmacology. – 2016. – Vol .2, №2 (3). – P. 9-15 [eLIBRARY] [Full text]

7. Diabetic foot syndrome: importance of microbiological monitoring and antimicrobial penetration of chemotherapeutic agents into the soft tissue lower limb in determining the treatment / T.N. Malorodova, T.G. Pokrovskaya, E.E. Kazakova, J.S. Urojevskaya // Research result: pharmacology and clinical pharmacology. – 2016. – Vol.2, №2 (3). – P. 91-98. [eLIBRARY] [Full text]

8. The nuclear factor – κB pathway in atherosclerosis: A potential therapeutic target for atherothrombotic vascular disease/ B.Pamukcu, G.Y. Lip, E. Shantsila // Thrombosis Research. – 2011.– Vol. 128 (2). – P. 117-123, doi: 10.1016/j.thromres.2011.03.025 [PubMed]

9. Nuclear factor κB: a potential therapeutic target in atherosclerosis and thrombosis / C. Monaco, E. Paleolog // Cardiovasc Res. – 2004 – 61 (4) – P. 671-682,doi: 10.1016/j.cardiores.2003.11.038 [PubMed] [Full text]

10. Overexpression of activated nuclear factor-κB in aorta of patients with coronary atherosclerosis / W. Zhang, S. Xing, X.L. Sun. // Clin Cardiol. – 2009. – 32 (12). – P. 42-47. doi:10.1002/clc.20482 [PubMed]

11. Induction of inflammatory mediators during reperfusion of the human heart / G. Valen, G. Paulsson, J. Vaage // Ann. Thorac. Surg. – 2001. – 71 (1). – P. 226-232. [PubMed]

12. Role of nuclear factor-κB activation in acute ischaemia-reperfusion injury in myocardium / A. Kiis, D.M. Yellon, G.F. Baxter // British Journal of Pharmacology. – 2003. – 138(5). – P. 894-900,doi:10.1038/sj.bjp.0705108. [Full text]

13. Sesquiterpene lactone parthenolide, an inhibitor of 1kB kinase complex and nuclear factor-κB, exerts beneficial effects in myocardial reperfusion injury / B. Zingarelli, P.W. Hake, A. Denenberg // Shock. – 2002. – 17 (2). – P. 127-34. [PubMed]

14. Pathophysiological roles of nuclear factor κB (NF-κB) in pulmonary arterial hypertension: effects of synthetic selective NF-κB inhibitor IMD-0354 / S. Hosokawa, G. Haraguchi, A. Sasaki [et al.] // Cardiovasc Res. – 2013 – 99 (1). – P. 35-43, doi: 10.1093/cvr/cvt105 [Full text]

15. NF-κB pathway in chronic kidney disease / G. Rangan, Y. Wang, D. Harris // Frontiers in Bioscience. – 2009. – 14. – P. 3496-3522 [PubMed]

16. Targeting the NF-κB pathway in asthma and chronic obstructive pulmonary disease / M.R. Edwards, N.W. Bartlett, D. Clarke [et al.] // Pharmacology & Therapeutics. – 2009. – Vol. 121 (1). – P. 1-13, doi: 10.1016/j.pharmthera.2008.09.003 [PubMed]

17. Schuliga, M. NF-κB signaling in chronic inflammatory airway disease / M. Schuliga // Biomolecules. – 2015. – 5 (3). – P. 1266-1283, doi: 10.3390/biom5031266 [PubMed][Full text]

18. Is NF-κB a useful therapeutic target in rheumatoid arthritis? / M. Feldmann, E. Andreakos, C. Smith [et al.] // Annals of the Rheumatic Diseases. – 2002. – 6 (2). – P. ii13-ii18. [Full text]

19. Signalling, inflammation and arthritis: NF-κB and its relevance to arthritis and inflammation / R.E. Simmonds, B.M. Foxwell // Rheumatology (Oxford). – 2008. – 47 (5). – P. 584-590, doi: 10.1093/rheumatology/kem298 [PubMed] [Full text]

20. Кайдашев, И.П. NF-κB-signaling as a basis for development of systemic inflammation, insulinoresistence, lipotokсicity, and sarcoplasmic diabetes type 2 and atherosclerosis / И.П. Кайдашев //
Nuclear factor kappa B as a potential target for pharmacological correction endothelium-associated pathology / V.A. Bagulina, D.A. Kostina, A.P. Doogan, V.E. Burda, S.V. Nadezhdin // Research results: pharmacology and clinical pharmacology. – 2017. – Vol. 3, №1. – P. 114-124.
RESEARCH RESULT:

PHARMACOLOGY AND CLINICAL PHARMACOLOGY

47. Cardiovascular effects of an arginase II selective inhibitor / V.I. Yakushev, M.V. Pokrovskii // Research result: pharmacology and clinical pharmacology. – 2016. – Vol. 2, №3. – P. 28-46. doi: 10.18413/2500-235X-2016-2-3-28-45 [Full text]

48. Gureev, V.V. New approaches of morfофундamental pharmacological correction of violations of cardiovascular system in experimental preeclampsia / V.V. Gureev // Research result: pharmacology and clinical pharmacology. – 2016. – Vol. 2, №3. – P. 11-27. doi: 10.18413/2500-235X-2016-2-3-11-27 [Full text]

49. Гурус В. В. Эндотелиальная дисфункция как центральное звено в патогенезе гестоза / Научные ведомости БелГУ. Серия: Медицина. Фармация. – 2012. – №4 (123). – С. 5-12. [eLIBRARY] [Full text]

50. Method of correction of endothelial dysfunction with combination of ademetionine and taurine / T.A. Khadieva, A.P. Dovgan, T.G. Pokrovsckaya // Research result: pharmacology and clinical pharmacology. – 2016. – Vol.2, №2. – P. 36-40 [eLIBRARY] [Full text]

51. Endothelial and cardioprotective effects of HMG-CoA-reductase in combination with L-arginine in endothelial dysfunction modeling / T.A. Denisyuk, G.A. Lazareva, V.Y. Provotorov, A.A. Shaposhnikov // Research result: pharmacology and clinical pharmacology. – 2016. – Vol. 2, №1 (2). – P. 4-8 [eLIBRARY] [Full text]

52. Nuclear factor κB signaling in atherosclerosis / M.P. de Winther, E. Kanters, G. Kraal [et al.] // Arterioscler Thromb Vasc Biol. – 2005. – 25 (5). – P. 904-914, doi: 10.1161/01.ATV.0000160340.72641.87 [PubMed] [Full text]

53. Endothelial NF-κBα as a mediator of kidney damage: the missing link between systemic vascular and renal disease / T.J. Guzik, D.G. Harrison // Circ Res. – 2007. – 101 (3). – P. 227-229, doi: 10.1161/CIRCRESAHA.107.158295 [PubMed] [Full text]

54. Nuclear factor κB activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans / G.L. Pierce, L.A. Lesniewski, B.R. Lawson [et al.] // Circulation. – 2009 – 119 (9) – P. 1284-1292, doi: 10.1161/CIRCULATIONAHA.108.804294 [PubMed] [Full text]

55. Oxidative stress and inflammatory mediators contribute to endothelial dysfunction in high-fat diet-induced obesity in mice / R. Kobayasi, E.H. Akamine, A.P. Davel [et al.] // Journal of Hypertension. – 2010 – Vol. 28 (10). – P. 2111–2119, doi: 10.1097/HJH.0b013e328336a68c [PubMed]

56. Role of NFkB in age-related vascular endothelial dysfunction in humans / A.J. Donato, G.L. Pierce, L.A. Lesniewski [et al.] // Aging. – 2009. – 1 (8). – P. 678-680 [Full text]

57. Chemokines in the vascular inflammatory response of atherosclerosis / A. Zernecke, C. Weber // Cardiovasc Res. – 2010. – 86 (2). – P. 192-201, doi: 10.1093/cvr/cvp391 [PubMed] [Full text]

58. The role of monocytes in atherosclerotic coronary artery disease / B. Pamukcu, G.Y. Lip, A. Devitt [et al.] // Annals Of Medicine. – 2010 – Vol. 42 (6). – P. 394-403 [PubMed]

59. The role of nuclear factor κB in cardiovascular health and disease / K. Van der Heiden, S. Cuhlmann, le A. Luong [et al.] // Clinical Science. – 2010. – 118 (10). – P. 593-605, doi: 10.1042/CS20090557 [PubMed] [Full text]

60. The role of nuclear factor κB in cardiovascular health and disease / K. Van der Heiden, S. Cuhlmann, le A. Luong [et al.] // Arterioscler Thromb Vasc Biol. – 2008. – 19 (10). – P. 2364-2367 [PubMed] [Full text]

61. Role of nuclear factor κB in cardiovascular health and disease / K. Van der Heiden, S. Cuhlmann, le A. Luong [et al.] // Arterioscler Thromb Vasc Biol. – 2008. – 19 (10). – P. 2364-2367 [PubMed] [Full text]

62. Role of nuclear factor κB in cardiovascular health and disease / K. Van der Heiden, S. Cuhlmann, le A. Luong [et al.] // Arterioscler Thromb Vasc Biol. – 2008. – 19 (10). – P. 2364-2367 [PubMed] [Full text]

63. Role of nuclear factor κB in cardiovascular health and disease / K. Van der Heiden, S. Cuhlmann, le A. Luong [et al.] // Arterioscler Thromb Vasc Biol. – 2008. – 19 (10). – P. 2364-2367 [PubMed] [Full text]

64. Role of nuclear factor κB in cardiovascular health and disease / K. Van der Heiden, S. Cuhlmann, le A. Luong [et al.] // Clinical Science. – 2010. – 118 (10). – P. 593-605, doi: 10.1042/CS20090557 [PubMed] [Full text]

65. Metabolic cardioprotection: new concepts in implementation of cardioprotective effects of meldonium / L.M. Danilenko, G.N. Klorochka, I.V. Kizilova, M.V. Korokin // Research result: pharmacology and clinical pharmacology. – 2016. – Vol.2, №3. – P. 95-100, doi: 10.18413/2500-235X-2016-2-3-95-100 [Full text]

66. Metabolic cardioprotection: new concepts in implementation of cardioprotective effects of meldonium / L.M. Danilenko, G.N. Klorochka, I.V. Kizilova, M.V. Korokin // Research result: pharmacology and clinical pharmacology. – 2016. – Vol.2, №3. – P. 95-100, doi: 10.18413/2500-235X-2016-2-3-95-100 [Full text]

67. Influence of recombinant erythropoietin on volume perfusion and morphological changes during reperfusion liver injury / A.A. Shaposhnikov, S.A. Alehin, G.A. Batishecheva, N.A. Bystrova, O.A. Osipova, A.V. Faitelson, S.V. Povetkin // International Journal of Pharmacy and Technology. – 2016. – Vol. 8, № 3. – P. 15189-15194 [eLIBRARY] [Full text]
68. Исследование поведенческих реакций при моделировании тотальной ишемии головного мозга / О.В. Мартынова, Л.А. Жилинкова, В.В. Гуреев, М.А. Мартынов, Е.А. Бехмельницкая, Д.А. Костина, О.В. Анциферов // Кубанский научный медицинский вестник. – 2015. – № 6 (155). – С. 77-82. [eLIBRARY] [Full text]

69. The features of neurological status when playing two – and fourvascular models of cerebral ischemia in rats / O.V. Martynova, O.V. Anciferov, V.V. Gureev A.A. Dolzhikov, K.M. Reznikov, A.A. Stepchenko, M.A. Martynov // International Journal of Pharmacy and Technology. – 2016. – Vol. 8, №2. – P. 14480-14485 [eLIBRARY] [Full text]

70. Pharmacological preconditioning by recombinant erythropoietin – a new way of treatment of retinal ischemia/reperfusion / A.S. Shabelnikova, A.A. Peresypkina, M.V. Pokrovskii, T.A. Shchegoleva, L.N. Sernov, K.M. Reznikov, S.B. Nikolaev, V.I. Shutov, V.D. Lutsenko, N.G. Philippenko // International Journal of Pharmacy and Technology. – 2016. – Vol. 8, Issue No.4. – P. 26889-26896. [Full text]

71. Pharmacological preconditioning by recombinant erythropoietin as the possibility of increasing the stability of tissue of the retina to reperfusion ischemia in experiment / A.S. Shabelnikova, A.A. Peresypkina, V.O. Gubareva, E.A. Levkova, A.A. Dolzhikov, S.B. Nikolaev, A.A. Stepchenko // Research result: pharmacology and clinical pharmacology. – 2016. – Vol. 2, №1 (2). – P. 25-29 [eLIBRARY] [Full text]

72. Биологические механизмы естественной цитопротекции – перспективное направление создания новых лекарственных препаратов для профилактики и лечения пренклампсии / М.В. Покровский, В.В. Гуреев, Е.Г. Ступакова, О.Е. Анциферова, Т.И. Локтева, Л.А. Жилинкова // Ведомости Научного центра экспертизы средств медицинского применения. – 2016. – № 4. – С. 20-27 [eLIBRARY] [Fulltext]

73. Роль К+АТФ каналов в реализации положительных эффектов резвератрола и никорандила при ADMA-подобной пренклампсии / В.В. Гуреев, Е.Г. Ступакова, Л.А. Жилинкова // Научные ведомости Белгородского государственного университета. Серия: Медицина. Фармацевия. – 2016. – Т. 35. № 19 (240). – С. 162-168 [eLIBRARY] [Full text]

74. Time course of coronary vascular endothelial adhesion molecule expression during reperfusion of the ischemic feline myocardium / A.S. Weyrich, M. Buerke, K.H. Albertine [et al.] // J. Leukocyte Biol. – 1999. – 57 (1). – P. 45-55 [PubMed]

75. Induction of inflammatory mediators during reperfusion of the human heart / G. Valen, G. Paulsson, J. Vaage // Ann. Thorac. Surg. – 2001. – 71 (1). – P. 226-232 [PubMed]

76. Nuclear factor-kappaB: its role in health and disease / A. Kumar, Y. Takada, A.M. Boriek [et al.] // J Mol Med (Berl). – 2004. – 82 (7). – P. 434-48 [PubMed]

77. Inhibition of nuclear factor kappa B (NF-B): an emerging theme in anti-inflammatory therapies / F. D'Acquisto, M.J. May, S. Ghosh // Mol Interv. – 2002. – 2 (1). – P. 22-35 [PubMed]

78. Induction of cytokines and ICAM-1 by proinflammatory cytokines in primary rheumatoid synovial fibroblasts and inhibition by N-acetyl-L-cysteine and aspirin / S. Sakurada, T. Kato, T. Okamoto // Int. Immunol. – 1996. – 8 (10). – P. 1483-1493 [PubMed]

79. Aspirin inhibits NF-kB and protects from angiotensin II-induced organ damage / D.N. Muller, V. Heissmeyer, R. Decheng [et al.] // FASEB J – 2001. – 15 (10). – P. 1822-4 [PubMed]

80. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice / T. Cyrus, S. Sung, L. Zhao [et al.] // Circulation. – 2002. – 106 (10). – P. 1282-1287, doi: 10.1161/01.CIR.0000027816.54430.96 [PubMed] [Full text]

81. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells / W. Dichtl, J. Dulak, M. Frick [et al.] // Arteriosclerosis, Thrombosis, and Vascular Biology. – 2003. – 23 (1). – P. 58-63, doi: 10.1161/01.ATV.0000043546.48735.20 [PubMed] [Full text]

82. Activation of the NF-kappa B and I kappa B system in smooth muscle cells after rat arterial injury. Induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1 / D.B. Landry, L.L. Couper, S.R. Bryant [et al.] // Am. J. Pathol. – 1997. – 151 (4). – P. 1085 1095 [Full text]

83. Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kB and AP-1 / P. Delerive, K. De Bosscher, S. Besnard [et al.] // J. Biol. Chem. – 1999. – 274 (45). – P. 32048-54, doi: 10.1074/jbc.274.45.32048 [PubMed]

84. Роль фенибраты в лечении микрососудистых осложнений сахарного диабета 2 типа / Л.В. Кошелев, Т.И. Романцов // Сахарный диабет. – 2009. – № 4. – С. 99-103 [eLIBRARY] [Full text]

85. Inhibiting NF-kB Activation by Small Molecules As a Therapeutic Strategy / S.C. Gupta, C. Sundaram, S. Reuter [et al.] // Biochimica et biophysica acta. – 2010. – 1799 (10-12). – P. 775-787, doi: 10.1016/j.bbagrm.2010.05.004 [PubMed] [Full text]

86. Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance / C. Bubici, S. Papa, K. Dean [et al.] // Oncogene. – 2006. – 25 (51). – P. 6731–674 [PubMed]

87. Inhibition of nuclear factor κB by phenolic antioxidants: interplay between antioxidant signaling and inflammatory cytokine expression / Q. Ma, K. Kinneer, J. Ye [et al.] // Molecular Pharmacology. – 2003. – 64 (2). – P. 211-219, doi: 10.1124/mol.64.2.211 [PubMed] [Full text]
Nuclear factor kappa B as a potential target for pharmacological correction endothelium-associated pathology / V.A. Ragulina, D.A. Kostina, A.P. Dovgan, V.E. Burda, S.V. Nadezhdin // Research result: pharmacology and clinical pharmacology. – 2017. – Vol. 3, №1 – P. 114-124.

88. Vasodilatory effects of cinnamic acid via the nitric oxide-cGMP-PKG pathway in rat thoracic aorta / Y.H. Kang, J.S. Kang, H.M. Shin // Phytother. Res. – 2013. – 27(2). – P. 205–211, doi:10.1002/ptr.4708 [PubMed]

89. Effects of cinnamic acid on expression of tissue factor induced by TNFalpha in endothelial cells and its mechanisms / X. Li, Z. Wen, X. He [et al.] // J Chin Med Assoc. – 2006. – 69(5). – P. 207-212, doi: 10.1016/S1726-4901(09)70220-5 [PubMed] [Full text]

90. Ezetimibe reduces cholesterol content and NF-kappa B activation in liver but not in intestinal tissue in guinea pigs / P. Fraunberger, E. Gröne, H.-J. Gröne, [et al.] // Journal of Inflammation. – 2017. – 14:3. – Режим доступа: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288872/ (дата обращения 02.02.2017)

91. Lapatinib–induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors / Y.J. Chen, M.H. Yeh, M.C. Yu [et al.] // Breast Cancer Research. – 2013. – 15(6) – R. 108, doi: 10.1186/bcr3575 [PubMed] [Full text]

92. Human adipocytes are highly sensitive to intermittent hypoxia induced NF-kappaB activity and subsequent inflammatory gene expression / C.T. Taylor, B.D. Kent, S.J. Crinion [et al.] // Biochemical and Biophysical Research Communications. – 2014. – Vol. 447 (4). – P. 660-665, doi: 10.1016/j.bbrc.2014.04.062 [PubMed]

93. C1P Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Preventing NF-kB Activation in Neutrophils / K. Baudiß, R. de Paula Vieira, S. Cicko [et al.] // J Immunol. – 2016. – 196 (5). – P. 2319-26, doi: 10.4049/jimmunol.1402681 [PubMed] [Full text]

94. Interleukin-1beta increases baseline expression and secretion of interleukin-6 by human uveal melanocytes in vitro via the p38 MAPK/NF-kappaB pathway / D.N. Hu, M. Chen, D.Y. Zhang [et al.] // Invest Ophthalmol Vis Sci. – 2011. – 52(6). – P. 3767-74, doi: 10.1167/iovs.10-36908 [PubMed] [Full text]

95. Alleviation of lung injury by glycyrrhizic acid in benzo(a)pyrene exposed rats: Probable role of soluble epoxide hydrolase and thioredoxin reductase / W. Qamar, R. Khan, A.Q. Khan // Toxicol. – 2012. – 291 (1-3). – P. 25-31, doi: 10.1016/j.tox.2012.09.004 [PubMed]

Ragulina Vera Alekseevna – PhD in Biological sciences, Associate Professor, Department of Biological chemistry.

Kostina Daria Alexandrovna – Graduate student of Department of Pharmacology.

Dovgan Anton Pavlovich – Graduate student of the Department of Pharmacology.

Burdy Yuri Evgenievich – PhD in Medical sciences, Associate Professor, Department of Pharmacology.

Nadezhdin Sergey Viktorovich – PhD in Biological sciences, Associate Professor, Head of the Experimental-Industrial Department «Cellular and Assisted Reproductive Technologies». 

---

Pharmacology and clinical pharmacology.